Clincosm LogoSign in Get a demo

A Study of Soticlestat Tablets in Healthy Adults

Sponsor
Takeda (Industry)
Overall Status
Completed
CT.gov ID
NCT05284760
Collaborator
(none)
96
Enrollment
1
Location
12
Arms
2.7
Actual Duration (Months)
35.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The main aim is to see how soticlestat tablets of different strengths work and to compare how it works alone in contrast to administration along with food.

In the study will be 2 groups of participants (part A and part B). Participants in part A will receive 300 mg of soticlestat administered in different kind of tablets (regular tablets, mini-tablets, commercial tablets) and participant in part B will also receive 300 mg of soticlestat in tablets but with food and crushed tablets with applesauce.

Participants will complete several assessments including clinical laboratory evaluations, physical examinations, Columbia-Suicide Severity Rating Scale (C-SSRS) assessment, electrocardiographs (ECGs), and vital signs.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

The drug being tested in this study is called soticlestat (TAK-935). The study will assess the bioequivalence, effect of food and tablet crushing, safety and tolerability following single oral dose of 3 different soticlestat oral tablet formulations in healthy participants.

The study will enroll approximately 96 participants. This study will be conducted in two parts (Part A and Part B) having 6 treatment sequences each. Participants will be randomly assigned (by chance, like flipping a coin) to one of the study parts as per treatment sequence:

  • Part A, Sequence 1: Treatment B + Treatment A + Treatment C

  • Part A, Sequence 2: Treatment A + Treatment C + Treatment B

  • Part A, Sequence 3: Treatment C + Treatment B + Treatment A

  • Part A, Sequence 4: Treatment B + Treatment C + Treatment A

  • Part A, Sequence 5: Treatment A + Treatment B + Treatment C

  • Part A, Sequence 6: Treatment C + Treatment A + Treatment B

  • Part B, Sequence 1: Treatment E + Treatment D + Treatment F

  • Part B, Sequence 2: Treatment D + Treatment F + Treatment E

  • Part B, Sequence 3: Treatment F + Treatment E + Treatment D

  • Part B, Sequence 4: Treatment E + Treatment F + Treatment D

  • Part B, Sequence 5: Treatment D + Treatment E + Treatment F

  • Part B, Sequence 6: Treatment F + Treatment D + Treatment E

This single center trial will be conducted in the United States. The overall duration of the study is approximately 51 days. Participants will be followed up for 14 days after the last dose of study drug for a follow-up assessment.

Study Design

Study Type:
Interventional
Actual Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Bioequivalence of Soticlestat Oral Tablet Formulations and the Effect of Food and Tablet Crushing on the Pharmacokinetics of Soticlestat in Healthy Adult Participants
Actual Study Start Date :
Mar 11, 2022
Actual Primary Completion Date :
May 22, 2022
Actual Study Completion Date :
Jun 2, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Part A, Sequence 1: Treatment B + Treatment A + Treatment C

Soticlestat T3 mini-tablets 300 milligram (mg), orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.

Drug: Soticlestat
Soticlestat T4 tablets.
Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part A, Sequence 2: Treatment A + Treatment C + Treatment B

    Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part A, Sequence 3: Treatment C + Treatment B + Treatment A

    Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T3 mini-tablets 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part A, Sequence 4: Treatment B + Treatment C + Treatment A

    Soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment B, followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment C, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment A. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part A, Sequence 5: Treatment A + Treatment B + Treatment C

    Soticlestat T4 tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment A, followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 2 under fasted condition as Treatment B, and followed by soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment C. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part A, Sequence 6: Treatment C + Treatment A + Treatment B

    Soticlestat T3 commercial tablets 300 mg, orally, once on Day 1 of Period 1 under fasted condition as Treatment C, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment A, and followed by soticlestat T3 mini-tablets 300 mg, orally, once on Day 1 of Period 3 under fasted condition as Treatment B. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part B, Sequence 1: Treatment E + Treatment D + Treatment F

    Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part B, Sequence 2: Treatment D + Treatment F + Treatment E

    Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part B, Sequence 3: Treatment F + Treatment E + Treatment D

    Soticlestat T4 300 mg tablets, crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part B, Sequence 4: Treatment E + Treatment F + Treatment D

    Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fed condition as Treatment E, followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 2 under fasted condition as Treatment F, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fasted condition as Treatment D. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part B, Sequence 5: Treatment D + Treatment E + Treatment F

    Soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 1 under fasted condition as Treatment D, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fed condition as Treatment E, and followed by soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 3 under fasted condition as Treatment F. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•
    Experimental: Part B, Sequence 6: Treatment F + Treatment D + Treatment E

    Soticlestat T4 300 mg tablets crushed and mixed with applesauce, orally, once on Day 1 of Period 1 under fasted condition as Treatment F, followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 2 under fasted condition as Treatment D, and followed by soticlestat T4 300 mg, tablets, orally, once on Day 1 of Period 3 under fed condition as Treatment E. A washout interval of exactly 4 days will be maintained between each Treatment Period.

    Drug: Soticlestat
    Soticlestat T4 tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat T3 mini-tablets.
    Other Names:
  • TAK-935

    • Drug: Soticlestat
    Soticlestat commercial tablets.
    Other Names:
  • TAK-935

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Cmax: Maximum Observed Plasma Concentration for Soticlestat [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose]

    2. AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose]

    3. AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Soticlestat [Day 1 pre-dose and at multiple time points (up to 96 hours) post-dose]

    Secondary Outcome Measures

    1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) [From screening up to 14 days after the last dose of soticlestat (Day 51)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 55 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Key Inclusion Criteria:

    1. Body mass index (BMI) greater than or equal to (>=) 18.0 and less than or equal to (<=) 32.0 kilogram per square meter (kg/m^2) at screening.

    2. Continuous non-smoker who has not used nicotine-containing products for at least 90 days prior to the first dosing.

    3. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, and ECGs, as deemed by the Investigator or designee.

    4. Able to swallow multiple tablets.

    Key Exclusion Criteria:

    1. History or presence of alcoholism or drug abuse within the past 2 years prior to the first dosing.

    2. Positive urine drug or alcohol results at screening or check-in.

    3. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

    4. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements within 14 days prior to the first dosing. Thyroid hormone replacement medication may be permitted if the participant has been on the same stable dose for the immediate 3 months prior to the first dosing.

    • Any drugs known to be significant inducers of cytochrome P450 (CYP) 3A, CYP2C19, uridine 5'-diphospho-glucuronosyltransferase (UGT) 1A9 or UGT2B4 enzymes and/or P-glycoprotein (P-gp), including St. John's Wort, within 28 days prior to the first dosing. Appropriate sources will be consulted to confirm lack of PK/pharmacodynamics interaction with study drug.

    1. History of alcohol consumption exceeding 2 standard drinks per day on average (1 glass is approximately equivalent to the following: beer [354 milliliter per 12 ounce {mL/12 oz}], wine [118 mL/4 oz], or distilled spirits [29.5 mL/1 oz] per day).

    2. Consumes excessive amounts, defined as greater than 4 servings (1 serving is approximately equivalent to 120mg of caffeine), of coffee, tea, cola, energy drinks, or other caffeinated beverages per day.

    3. Has been on a diet incompatible with the on-study diet, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study.

    4. Donation of blood or significant blood loss within 56 days prior to the first dosing.

    5. Plasma donation within 7 days prior to the first dosing.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Celerion Tempe Arizona United States 85283

    Sponsors and Collaborators

    • Takeda

    Investigators

    • Study Director: Study Director, Takeda

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Takeda
    ClinicalTrials.gov Identifier:
    NCT05284760
    Other Study ID Numbers:
    • TAK-935-1014
    First Posted:
    Mar 17, 2022
    Last Update Posted:
    Jun 6, 2022
    Last Verified:
    Jun 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Takeda
    Drug Therapy

    Study Results

    No Results Posted as of Jun 6, 2022